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Heterozygous mutations in GATA2 underlie different syndromes, previously described as monocytopenia
and mycobacterial avium complex infection (MonoMAC); dendritic cell, monocytes, B- and NK lym-
phocytes deﬁciency (DCML); lymphedema, deafness and myelodysplasia (Emberger syndrome) and fa-
miliar myelodysplastic syndrome/acute myeloid leukemia (MDS / AML). Onset and severity of clinical
symptoms vary and preceding cytopenias are not always present.
We describe a case of symptomatic DCML deﬁciency and rather discrete bone marrow ﬁndings due to
GATA2 mutation. Exome sequencing revealed a somatic ASXL1 mutation and the patient underwent al-
logeneic stem cell transplantation successfully.
& 2015 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The transcription factor GATA2 has a complex role in the devel-
opment of hematopoiesis and lymphopoiesis but even in differentia-
tion of non-hematopoietic progenitors. Haploinsufﬁciency of GATA2
leads to a variety of clinical and laboratory ﬁndings. It has been pre-
viously described that heterozygous mutations in GATA2 underlie
different syndromes deﬁned by monocytopenia and mycobacterial
avium complex infection (MonoMAC), deﬁciency of dendritic cells,
monocytes, B- and NK lymphocytes (DCML), lymphedema, deafness
and myelodysplasia (Emberger syndrome) or familiar myelodysplastic
syndrome/acute myeloid leukemia (MDS/AML) [1–3].
Different types of mutations are known to cause loss of func-
tion of the mutated allele leading to haploinsufﬁciency of GATA2,
and a correlation with certain clinical symptoms has been de-
scribed in some cases [4–6]. Germline mutations of GATA2 aren open access article under the C
logy and Vascular Disorders,
menga).transmitted with autosomal dominant inheritance. However, even
among hereditary cases, there is a great variation of clinical ﬁnd-
ings, time of manifestation and even severity of disease in patients
with GATA2 mutations. Clinical characteristics in most patients
include immunodeﬁciency with susceptibility to human papillo-
mavirus (HPV) and non-tuberculous mycobacteria (NTM), predis-
position to MDS/AML, pulmonary proteinosis (PAP) and congenital
lymphedema. These symptoms might occur with or without pre-
ceding cytopenias and different medical specialties are involved in
the diagnosis and management of these patients. The only curative
treatment so far is allogeneic hematopoietic stem cell transplan-
tation (allo-HSCT). Therefore, it is crucial to diagnose patients with
GATA2 mutations as early as possible.
We report a case of DCML deﬁciency and MDS in a patient with
GATA2 mutation who successfully underwent allogeneic stem cell
transplantation.2. Case report
A 38-year old woman presented at the Department of Hema-
tology, Lund University hospital in January 2011 with microcyticC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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she has been treated for severe and recurrent condylomata. During
the last 10 years, she had gone repeatedly through surgical inter-
vention for severe condylomata, that were positive for HPV type 6.
Additionally, the patient has been treated for recurrent pneumo-
nia. Due to work related reasons, she had moved within Europe
several times. Already at the age of 12, she was diagnosed with
anemia in Germany, presumably caused by iron deﬁciency. Due to
persisting anemia, a bone marrow biopsy was done in the Neth-
erlands in 2008 and she was diagnosed with MDS refractory an-
emia (RA), IPSS low, normal karyotype. She has never required
blood transfusions.
At presentation, she had adapted to a hemoglobin level of 79 g/
l and had only occasional discrete symptoms of her anemia, as
fatigue, other constitutional symptoms were absent. She described
her menstruation as mostly normal, but sometimes heavy and
prolonged due to known uterine myoma. She had no other history
of bleeding. Platelets and WBC count were normal. Differential
blood counts showed a discrete lymphopenia and complete ab-
sence of monocytes. A lymphocyte proﬁle showed low levels of
NK-cells (0.02109), CD4 T-cells (0.12109) and B-cells
(0.01109). We performed a new bone marrow biopsy in 2012 in
which the previous diagnosis of MDS RA could be conﬁrmed even
if signs of dysplasia were rather discrete with mainly dysplastic
megakaryocytes. No ﬁbrosis was found (Fig. 1). The bone marrow
cells still showed a normal karyotype in routine cytogenetics. She
did respond to oral iron substitution to some degree with Hb
around 90 g/l.Fig. 1. Morphology of the bone marrow biopsy before treatment. (A) May-Giemsa Grün
age of 37, with normally distributed megakaryocytes. (B) MGG, 40: some dysplastic m
content of reticulin ﬁbers.Clinical ﬁndings of symptomatic severe HPV infection, re-
current pneumonia and warts/condylomata in combination with
the diagnosis of MDS RA and monocytopenia/lymphopenia, led to
the suspicion of DCML syndrome. The family history revealed no
individuals with similar symptoms. In particular, no other family
members are known to be affected by any type of hematological
malignancy or immunodeﬁciency (Fig. 2 A). Sequencing of mate-
rial from both bone marrow and skin biopsy showed a hetero-
zygous frameshift mutation in GATA2 (NM_001145661.1:c.404dup;
Gly136Argfs*49) (Fig. 2, B–D). The patient's parents were tested
but no GATA2 mutation could be detected (Fig. 2 C), suggesting
that the patients disorder was caused by a de-novo mutation. To
systematically screen for additional mutations, we performed
exome sequencing of matched tumor (bone-marrow) and normal
(skin biopsy) samples as described previously [7,8]. Thereby, we
detected a somatic ASXL1 mutation (NM_015338.4:c.2077 C4T;
Arg693*) (Fig. 2 D).
Since no matched sibling donor was available, a search in the
registry was initiated and a suitable unrelated donor with a HLA
match 16/18 (difference in HLA-DPA- and HLA-DPB1-antigen), full
blood group match and CMV match could be identiﬁed. After re-
duced conditioning with ﬂudarabine 30 mg/m2 for 3 days and TBI
2 Gy, she underwent allo-HSCT with peripheral blood stem cells in
June 2013. As GvHD prophylaxis, cyclosporin A and mycophenolate
mofetil were given.
Already 4 weeks after allo-HSCT she achieved an almost normal
differential WBC count with monocytes around 1109, total lym-
phocytes of 0.6109. A new lymphocyte proﬁle showed an almostwald (MGG), 10: cellularity around 40%, considered to be normal for the patients
egakaryocytes (arrow) with hypolobulated nuclei. (C) Gomori silver stain: normal
Fig. 2. Molecular diagnostic and genetic workup. (A) Pedigree of the affected family. Arrow indicates the index patient. (B) Germline mutation Gly136Argfs*49 mapped to the
GATA2 protein structure using the software DOG1.0 [9]. (C) Genetic testing of the affected family by Sanger sequencing. Chromatograms of the index patient and her parents
show a partial sequence of GATA2 exon 3 surrounding the cDNA position 404. (D) Exome sequence data from the index patient supporting the GATA2 germline mutation and
the somatic ASXL1 mutation. Alignments of matched tumor (bone marrow) and normal (skin biopsy) samples from the index patient are shown using the Integrative
Genomics Viewer (IGV) [10]. Read counts of reference and variant alleles at the altered positions are indicated for each sample.
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She showed a full donor blood chimerism in October 2013.
Eight weeks after allo-HSCT, she experienced a severe men-
strual bleeding accompanied by some chest discomfort and fati-
gue. Clinical investigation revealed a hemoglobin level of around
70g/l and discrete ECG changes. Subsequently, coronary angio-
graphy was performed showing a subtotal stenosis of the proximal
left anterior descendens (LAD) coronary artery without any other
signs of atherosclerosis. Percutaneous transluminal coronaryangioplasty (PTCA) was done and antiplatelet therapy with clopi-
dogrel was initiated. She underwent hystero-salpingectomy after
antiplatelet therapy was terminated. The patient has neither car-
diac risk factors nor a family history of heart disease.
At 4 months she developed a mild graft-versus host disease
(GvHD grade 1) with skin rashes, mild eosinophilia and muscu-
loskeletal pain, responding to an intermediate steroid dose.
Around the same time, both warts and condylomata disappeared
gradually.
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In this case report we describe a young woman that presented
with a long history of condylomata and microcytic anemia due to a
combination of MDS associated with the DCML syndrome and iron
deﬁciency demonstrating that an overlap of clinical symptoms
may complicate diagnosis in patients with GATA2 mutations. Ge-
netic lesions in GATA2 that lead to Emberger syndrome seem to be
affecting endothelial cells of the lymphatic system, but vascular
problems have not been described in patients with GATA2 muta-
tions, to our knowledge. Our patient suffered from a non-ST-ele-
vation myocardial infarction (NSTEMI) caused by a stenosis in the
LAD in the absence of cardiac risk factors or a family history of
heart disease and is, thus, most likely triggered by anemia due to a
massive menstrual bleeding aggravated by a uterine myoma. Some
clinical ﬁndings may be associated with distinct type of mutation
causing GATA2 haploinsufﬁciency. However, in two large patient
cohorts published recently, diversity of phenotype in patients with
GATA2 mutations was shown for the ﬁrst time [4,11]. 84% of the
patients in this study met the diagnostic criteria for MDS whereas
bone marrow ﬁndings in patients with GATA2 mutations seem to
differ from those with typical MDS [4]. Instead, patients with
GATA2 mutations present with a hypocellular bone marrow, in-
creased reticulin ﬁbrosis and atypical megakaryocytes in almost all
cases. In addition cytogenetic abnormalities such as monosomy
7 or trisomy 8 are frequent [12,13]. In the case presented here,
repeated bone marrow biopsies showed rather discrete changes
and considering the absence of cytogenetic aberrations, it was
challenging to diagnose MDS. Nevertheless, exome sequencing
revealed the presence of a somatic ASXL1 mutation. Myeloid
transformation induced by acquired lesions of ASXL1 in patients
with constitutional GATA2 mutations were previously reported
[12–14]. This demonstrates that an early diagnosis and evaluation
for allo-HSCT is crucial for patients with GATA2 mutations and
genetic counseling should be offered to affected families.References
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